EBOla Post-Exposure Prophylaxis

Launched by ANRS, EMERGING INFECTIOUS DISEASES · Feb 18, 2025

Keywords

ClinConnect Summary

The EBO-PEP trial is a study designed to test new ways to prevent Ebola Virus Disease (EVD) in people who are at high risk of getting the virus after being in contact with someone who has it. This trial will include individuals who have had direct contact with someone showing symptoms of EVD, like diarrhea or vomiting, or with the body fluids of someone infected. To participate, individuals must be at least 6 months old, have had their last contact within the last 5 days, and show no signs of EVD.

Participants will be divided into two groups: one will receive a vaccine called Ervebo, while the other will receive Ervebo along with another treatment called Inmazeb, followed by a second dose of the vaccine later. Throughout the trial, participants will be closely monitored for at least 21 days, with regular visits to a health center and daily check-ins to ensure their health and safety. If any symptoms of EVD develop, participants will be assessed and treated at a specialized Ebola Treatment Center. This study aims to find the best way to protect those who are most vulnerable to this serious disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Last high-risk contact within the last 5 days
• • No signs or symptoms of EVD
• • Age ≥ 6 months
• • Signed and dated informed consent (by a representative of parental authority for minors).
• Exclusion Criteria:
• • Previous vaccination with Ervebo or any other EVD vaccine less than 5 years ago (declared by the participant)
• • History of confirmed EVD less than 5 years ago (declared by the participant);
• • Hypersensitivity to one of the investigational medicinal products (IMP) or to their excipients (declared by the participant)
• • Participation in another therapeutic or vaccination trial for EVD
• • Any other reason which, at the investigator's discretion, would compromise the participant's safety and cooperation in the trial.